Cadrenal Therapeutics (NASDAQ:CVKD) Trading 14.3% Higher – Time to Buy?

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD)’s share price rose 14.3% during mid-day trading on Wednesday . The stock traded as high as $20.63 and last traded at $19.89. Approximately 125,227 shares traded hands during mid-day trading, an increase of 114% from the average daily volume of 58,609 shares. The stock had previously closed at $17.40.

Analyst Upgrades and Downgrades

Separately, HC Wainwright raised their price objective on shares of Cadrenal Therapeutics from $3.00 to $32.00 and gave the stock a “buy” rating in a research note on Monday, November 11th.

Cadrenal Therapeutics Trading Up 14.3 %

The firm has a 50 day simple moving average of $14.85. The company has a market cap of $35.40 million, a price-to-earnings ratio of -2.98 and a beta of 1.26.

Cadrenal Therapeutics (NASDAQ:CVKD) last issued its earnings results on Thursday, November 7th. The company reported ($2.18) EPS for the quarter, missing the consensus estimate of ($1.83) by ($0.35). As a group, sell-side analysts expect that Cadrenal Therapeutics, Inc. will post -7.59 earnings per share for the current fiscal year.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.